Skip to main content
SpringerLink
Log in

Current Concepts in the Therapy of the Spondyloarthritides

  • Therapy Review
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Recent success in the treatment of patients with the more severe forms of spondyloarthritides (SpA) has dramatically changed old paradigms. There is evidence that anti-tumor necrosis factor (TNF)-α therapy is highly effective in SpA, especially in ankylosing spondylitis (AS) and psoriatic arthritis. Based on recent data on more than 1000 patients with AS and psoriatic arthritis, this treatment seems to be even more effective than in rheumatoid arthritis (RA). The currently available anti-TNFα agents, infliximab, etanercept, and adalimumab, are approved for the treatment of RA in the US and in Europe. TNFα blockers may even be considered as a first-line treatment in patients with active AS whose condition is not sufficiently controlled with NSAIDs, as in the case of axial disease. There is preliminary evidence that both agents also work in other SpA, such as undifferentiated SpA. There is hope that ankylosis may be preventable, but it remains to be shown whether patients benefit from long-term anti-TNFα therapy and whether radiologic progression and ankylosis can be stopped. Furthermore, it seems that anti-TNFα therapy can also improve clinical manifestations of other inflammatory spinal disorders, such as sciatica and back pain caused by disc herniation, or possibly even intermittent inflammatory states of degenerative disc disease. Severe adverse events from treatment with anti-TNFα continue to be rare. Tuberculosis can be largely prevented by appropriate screening. As it stands now, the benefits of anti-TNFα therapy in AS seem to outweigh the shortcomings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Braun J, Bollow M, Remlinger G, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998; 41(1): 58–67

    Article  PubMed  CAS  Google Scholar 

  2. Brandt J, Bollow M, Haberle J, et al. Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: many, but not all patients with sacroiliitis have spondyloarthropathy. Rheumatology (Oxford) 1999; 38(9): 831–6

    Article  CAS  Google Scholar 

  3. Gran JT, Husby G, Hordvik M. Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, northern Norway. Ann Rheum Dis 1985; 44(6): 359–67

    Article  PubMed  CAS  Google Scholar 

  4. Saraux A, Guedes C, Allain J, et al. Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France: Societe de Rhumatologie de l’Ouest. J Rheumatol 1999; 26(12): 2622–7

    PubMed  CAS  Google Scholar 

  5. Lautermann D, Braun J. Ankylosing spondylitis: cardiac manifestations. Clin Exp Rheumatol 2002; 20(6 Suppl. 28): S11–5

    PubMed  CAS  Google Scholar 

  6. Zink A, Braun J, Listing J, et al. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis: results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 2000; 27(3): 613–22

    PubMed  CAS  Google Scholar 

  7. Ward MM. Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res 1999; 12(4): 247–55

    Article  PubMed  CAS  Google Scholar 

  8. Braun J, Pincus T. Mortality, course of disease and prognosis of patients with ankylosing spondylitis. Clin Exp Rheumatol 2002; 20(6 Suppl. 28): S16–22

    PubMed  CAS  Google Scholar 

  9. Leirisalo-Repo M. Prognosis, course of disease, and treatment of the spondyloarthropathies. Rheum Dis Clin North Am 1998; 24(4): 737–51

    Article  PubMed  CAS  Google Scholar 

  10. Amor B, Dougados M, Khan MA. Management of refractory ankylosing spondylitis and related spondyloarthropathies. Rheum Dis Clin North Am 1995; 21(1): 117–28

    PubMed  CAS  Google Scholar 

  11. Ward MM. Predictors of the progression of functional disability in patients with ankylosing spondylitis. J Rheumatol 2002; 29(7): 1420–5

    PubMed  Google Scholar 

  12. van Tubergen A, Landewe R, van der Heijde D, et al. Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 2001; 45(5): 430–8

    Article  PubMed  Google Scholar 

  13. Braun J, Sieper J. Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches. Arthritis Res 2002; 4(5): 307–21

    Article  PubMed  CAS  Google Scholar 

  14. Braun J, van der Heijde D. Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides. Expert Opin Investig Drugs 2003; 12(7): 1097–109

    Article  PubMed  CAS  Google Scholar 

  15. Maini R, Breedveld FC, Kalden JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004; 50: 1051–65

    Article  PubMed  CAS  Google Scholar 

  16. Wagner CL, Schantz A, Barnathan E, et al. Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev Biol (Basel) 2003; 112: 37–53

    CAS  Google Scholar 

  17. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003; 348(7): 601–8

    Article  PubMed  CAS  Google Scholar 

  18. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 2004; 126(2): 402–13

    Article  PubMed  CAS  Google Scholar 

  19. Braun J, Sieper J. The sacroiliac joint in the spondyloarthropathies. Curr Opin Rheumatol 1996; 8(4): 275–87

    Article  PubMed  CAS  Google Scholar 

  20. McGonagle D, Gibbon W, O’Connor P, et al. Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum 1998; 41(4): 694–700

    Article  PubMed  CAS  Google Scholar 

  21. Braun J, Bollow M, Eggens U, et al. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum 1994; 37(7): 1039–45

    Article  PubMed  CAS  Google Scholar 

  22. Muche B, Bollow M, Francois RJ, et al. Anatomic structures involved in early- and late-stage sacroiliitis in spondylarthritis: a detailed analysis by contrast-enhanced magnetic resonance imaging. Arthritis Rheum 2003; 48(5): 1374–84

    Article  PubMed  CAS  Google Scholar 

  23. Laloux L, Voisin MC, Allain J, et al. Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 2001; 60(4): 316–21

    Article  PubMed  CAS  Google Scholar 

  24. Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995. 38(4): 499–505

    Article  PubMed  CAS  Google Scholar 

  25. Bollow M, Fischer T, Reisshauer H, et al. Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis-cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 2000; 59(2): 135–40

    Article  PubMed  CAS  Google Scholar 

  26. Mielants H, Veys EM. HLA-B27 related arthritis and bowel inflammation. Part 1: sulfasalazine (salazopyrin) in HLA-B27 related reactive arthritis. J Rheumatol 1985; 12(2): 287–93

    PubMed  CAS  Google Scholar 

  27. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999; 5(2): 119–33

    Article  PubMed  CAS  Google Scholar 

  28. Rutgeerts P, Lemmens L, Van Assche G, et al. Treatment of active Crohn’s disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther 2003; 17(2): 185–92

    Article  PubMed  CAS  Google Scholar 

  29. Van den Bosch F, Kruithof E, Baeten D, et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000; 59(6): 428–33

    Article  PubMed  Google Scholar 

  30. Stone M, Salonen D, Lax M, et al. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol 2001; 28(7): 1605–14

    PubMed  CAS  Google Scholar 

  31. Breban M, Vignon E, Claudepierre P, et al. Efficacy of infliximab in refractory ankylosing spondylitis (AS): results of a six-month open label study. Rheumatology (Oxford) 2002; 41(11): 1280–5

    Article  CAS  Google Scholar 

  32. Braun J, Brandt J, Listing J, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003; 48(8): 2224–33

    Article  PubMed  CAS  Google Scholar 

  33. Kruithof E, Van den Boschv F, Baeten D, et al. Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis 2002; 61(3): 207–12

    Article  PubMed  CAS  Google Scholar 

  34. Maksymowych WP, et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 2002; 29(5): 959–65

    PubMed  CAS  Google Scholar 

  35. Collantes-Estevez E, Munoz-Villanueva MC, Canete-Crespillo JD, et al. Infliximab in refractory spondyloarthropathies: a multicentre 38 week open study. Ann Rheum Dis 2003; 62(12): 1239–40

    Article  PubMed  CAS  Google Scholar 

  36. Brandt J, Haibel H, Comely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000; 43(6): 1346–52

    Article  PubMed  CAS  Google Scholar 

  37. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21(12): 2286–91

    PubMed  CAS  Google Scholar 

  38. Braun J, Brandt J, Listing J, et al. Two-year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis. In press

  39. Rudwaleit M, Listing J, Brandt J, et al. Prediction of a major clinical response (BASDAI 50) to TNF-α blockers in ankylosing spondylitis. Ann Rheum Dis 2004; 63(6): 665–70

    Article  PubMed  CAS  Google Scholar 

  40. Allali F, Breban M, Porcher R, et al. Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha. Ann Rheum Dis 2003; 62(4): 347–9

    Article  PubMed  CAS  Google Scholar 

  41. Temekonidis TI, Alamanos Y, Nikas SN, et al. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Ann Rheum Dis 2003; 62(12): 1218–20

    Article  PubMed  CAS  Google Scholar 

  42. Braun J, Baraliakos X, Golder W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003; 48(4): 1126–36

    Article  PubMed  CAS  Google Scholar 

  43. Marzo-Ortega H, McGonagle D, O’Connor P, et al. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 2001; 44(9): 2112–7

    Article  PubMed  CAS  Google Scholar 

  44. Gorman JD, Sack KE, Davis JC, et al. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346(18): 1349–56

    Article  PubMed  CAS  Google Scholar 

  45. Davis JC, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48(11): 3230–6

    Article  PubMed  CAS  Google Scholar 

  46. Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003; 48(6): 1667–75

    Article  PubMed  CAS  Google Scholar 

  47. Antoni C, Braun J. Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol 2002; 20(6 Suppl. 28): S152–7

    PubMed  CAS  Google Scholar 

  48. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003; 48(11): 3013–22

    Article  PubMed  CAS  Google Scholar 

  49. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345(15): 1098–104

    Article  PubMed  CAS  Google Scholar 

  50. Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48(8): 2122–7

    Article  PubMed  CAS  Google Scholar 

  51. Baeten D, Kruithof E, Van den Bosch F, et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003; 62(9): 829–34

    Article  PubMed  CAS  Google Scholar 

  52. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46(12): 3151–8

    Article  PubMed  CAS  Google Scholar 

  53. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001; 44(12): 2862–9

    Article  PubMed  CAS  Google Scholar 

  54. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors and the effect of anti-tumor necrosis factor therapy. Am J Med 2004; 116(5): 305–11

    Article  PubMed  Google Scholar 

  55. Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002; 86(2-3): 123–30

    Article  PubMed  Google Scholar 

  56. Charles PJ, Smeenk RJ, De Jong J, et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000; 43(11): 2383–90

    Article  PubMed  CAS  Google Scholar 

  57. De Rycke L, Kruithof E, Van Damme N, et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003; 48(4): 1015–23

    Article  PubMed  Google Scholar 

  58. Shakoor N, Michalska M, Harris CA, et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002; 359(9306): 579–80

    Article  PubMed  CAS  Google Scholar 

  59. Cheifetz A, Michaud K, Anderson J, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98(6): 1315–24

    Article  PubMed  CAS  Google Scholar 

  60. Wolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50(2): 372–9

    Article  PubMed  CAS  Google Scholar 

  61. Food and Drug Administration, Center for Biologies Evaluation and Research. Safety update on TNF-alpha antagonists: infliximab and etanercept [online]. Available from: www.fda.gov (Accessed 2001)

  62. Manadan A, Mohan A, Cote TR, et al. Tuberculosis and etanercept treatment [abstract]. Arthritis and Rheumatism 2002; 46Suppl. 9: 166

    Google Scholar 

  63. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001; 344(14): 1099–100

    Article  PubMed  CAS  Google Scholar 

  64. Slifman NR, Gershon SK, Lee JH, et al. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003; 48(2): 319–24

    Article  PubMed  CAS  Google Scholar 

  65. Gluck T, Linde HJ, Scholmerich J, et al. Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases. Arthritis Rheum 2002; 46(8): 2255–7

    Article  PubMed  CAS  Google Scholar 

  66. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002; 46(10): 2565–70

    Article  PubMed  CAS  Google Scholar 

  67. Kwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 138(10): 807–11

    PubMed  Google Scholar 

  68. DeBandt M, Descamps V, Meyer O. Two cases of etanercept-induced systemic lupus erythematosus in patients with rheumatoid arthritis [abstract]. Ann Rheum Dis 2001; 60: 175

    Google Scholar 

  69. Debandt M, Vittecoq O, Descamps V, et al. Anti-TNFα-induced systemic lupus syndrome. Clin Rheumatol 2003; 22(1): 56–61

    Article  PubMed  CAS  Google Scholar 

  70. Brion PH, Mittal-Henkle A, Kalunian KC. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis [letter]. Ann Intern Med 1999; 131(8): 634

    PubMed  CAS  Google Scholar 

  71. Soliotis F, Glover M, Jawad AS. Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis. Ann Rheum Dis 2002; 61(9): 850–1

    Article  PubMed  CAS  Google Scholar 

  72. Jarrett SJ, Cunnane G, Conaghan PG, et al. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol 2003; 30(10): 2287–91

    PubMed  Google Scholar 

  73. Olivieri I, Padula A, Ciancio G, et al. Successful treatment of SAPHO syndrome with infliximab: report of two cases. Ann Rheum Dis 2002; 61(4): 375–6

    Article  PubMed  CAS  Google Scholar 

  74. Wagner AD, Andresen J, Jendro MC, et al. Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum 2002; 46(7): 1965–8

    Article  PubMed  Google Scholar 

  75. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359(9313): 1187–93

    Article  PubMed  CAS  Google Scholar 

  76. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21(12): 2281–5

    PubMed  CAS  Google Scholar 

  77. Davis J, van der Heijde D, Dougados M, et al. Baseline factors influential on ASAS 20 response in ankylosing spondylitis patients treated with etanercept (ENBREL®). Arthritis and Rheumatism 2003; 48(9 Suppl.): S440

    Google Scholar 

  78. Burke JG, Watson RW, McCormack D, et al. Intervertebral discs which cause low back pain secrete high levels of proinflammatory mediators. J Bone Joint Surg Br 2002; 84(2): 196–201

    Article  PubMed  CAS  Google Scholar 

  79. Goupille P, Jayson MI, Valat JP, et al. The role of inflammation in disk herniation-associated radiculopathy. Semin Arthritis Rheum 1998; 28(1): 60–71

    Article  PubMed  CAS  Google Scholar 

  80. Kawakami M, Tamaki T, Hayashi N, et al. Possible mechanism of painful radiculopathy in lumbar disc herniation. Clin Orthop 1998; (351): 241–51

  81. Olmarker K, Rydevik B, Nordborg C. Autologous nucleus pulposus induces neurophysiologic and histologic changes in porcine cauda equina nerve roots. Spine 1993; 18(11): 1425–32

    PubMed  CAS  Google Scholar 

  82. Bobechko WP, Hirsch C. Auto-immune response to nucleus pulposus in the rabbit. J Bone Joint Surg Br 1965; 47: 574–80

    PubMed  CAS  Google Scholar 

  83. Shubayev VI, Myers RR. Upregulation and interaction of TNFalpha and gelatinases A and B in painful peripheral nerve injury. Brain Res 2000; 855(1): 83–9

    Article  PubMed  CAS  Google Scholar 

  84. Igarashi T, Kikuchi S, Shubayev V, et al. 2000 Volvo Award winner in basic science studies: exogenous tumor necrosis factor-alpha mimics nucleus pulposus-induced neuropathology. Molecular, histologic, and behavioral comparisons in rats. Spine 2000; 25(23): 2975–80

    Article  PubMed  CAS  Google Scholar 

  85. Byrod G, Rydevik B, Johansson BR, et al. Transport of epidurally applied horseradish peroxidase to the endoneurial space of dorsal root ganglia: a light and electron microscopic study. J Peripher Nerv Syst 2000; 5(4): 218–26

    Article  PubMed  CAS  Google Scholar 

  86. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988; 23(4): 339–46

    Article  PubMed  CAS  Google Scholar 

  87. Otani K, Aral I, Mao G, et al. Nucleus pulposus induced nerve root injury: relationship betwenn blood flow and nerve conduction velocity. J Neurosurg 1999; 45: 614–9

    Article  CAS  Google Scholar 

  88. Aoki Y, Rydevik B, Kikuchi S, et al. Local application of disc-related cytokines on spinal nerve roots. Spine 2002; 27(15): 1614–7

    Article  PubMed  Google Scholar 

  89. Okamoto K, Martin DP, Schmelzer JD, et al. Pro- and anti-inflammatory cytokine gene expression in rat sciatic nerve chronic constriction injury model of neuropathic pain. Exp Neurol 2001; 169(2): 386–91

    Article  PubMed  CAS  Google Scholar 

  90. Olmarker K. Radicular pain: recent pathophysiologic concepts and therapeutic implications. Schmerz 2001; 15(6): 425–9

    Article  PubMed  CAS  Google Scholar 

  91. Brattsand R, Linden M. Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment Pharmacol Ther 1996; 10Suppl. 2: 81–90

    PubMed  CAS  Google Scholar 

  92. Bluthe RM, Dantzer R, Kelley KW. Interleukin-1 mediates behavioural but not metabolic effects of tumor necrosis factor alpha in mice. Eur J Pharmacol 1991; 209(3): 281–3

    Article  PubMed  CAS  Google Scholar 

  93. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385(6618): 729–33

    Article  PubMed  CAS  Google Scholar 

  94. Baumgartner RA, Deramo VA, Beaven MA. Constitutive and inducible mechanisms for synthesis and release of cytokines in immune cell lines. J Immunol 1996; 157(9): 4087–93

    PubMed  CAS  Google Scholar 

  95. Karppinen J, Korhonen T, Malmivaara A, et al. Tumor necrosis factor-alpha monoclonal antibody, infliximab, used to manage severe sciatica. Spine 2003; 28(8): 750–3

    PubMed  Google Scholar 

  96. Myers RR. 1994 ASRA lecture: the pathogenesis of neuropathic pain. Reg Anesth 1995; 20(3): 173–84

    PubMed  CAS  Google Scholar 

  97. Mixter W. Rupture of the intervertebral disk with involvement of the spinal canal. N Engl J Med 1934; 211: 210–5

    Article  Google Scholar 

  98. Wells MR, Racis SP, Vaidya U. Changes in plasma cytokines associated with peripheral nerve injury. J Neuroimmunol 1992; 39(3): 261–8

    Article  PubMed  CAS  Google Scholar 

  99. Olmarker K, Rydevik B. Selective inhibition of tumor necrosis factor-alpha prevents nucleus pulposus-induced thrombus formation, intraneural edema, and reduction of nerve conduction velocity: possible implications for future pharmacologic treatment strategies of sciatica. Spine 2001; 26(8): 863–9

    Article  PubMed  CAS  Google Scholar 

  100. Amor B, Santos RS, Nahal R, et al. Predictive factors for the longterm outcome of spondyloarthropathies. J Rheumatol 1994; 21(10): 1883–7

    PubMed  CAS  Google Scholar 

  101. Jayson MI. Leonard Trask: the wonderful invalid: the first American description of ankylosing spondylitis. Arthritis Rheum 2003; 48(3): 612–3

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

No funding was used to assist in the preparation of this manuscript. There are no conflicts of interest that are directly relevant to the contents of this manuscript.

Author information

Authors and Affiliations

  1. Rheumazentrum Ruhrgebiet, Landgrafenstr. 15, Herne, 44652, Germany

    Xenofon Baraliakos &  Juergen Braun

  2. Ruhr-University, Bochum, Germany

    Xenofon Baraliakos &  Juergen Braun

Authors
  1. Xenofon Baraliakos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Juergen Braun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Juergen Braun.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baraliakos, X., Braun, J. Current Concepts in the Therapy of the Spondyloarthritides. BioDrugs 18, 307–314 (2004). https://doi.org/10.2165/00063030-200418050-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200418050-00003

Keywords

Search

Navigation